AI is no longer a peripheral tool in drug development. It is reshaping how trials are designed, run, and completed, and the pace of change is accelerating.
In this episode of the Drug Discovery World Podcast, Suzanne Caruso, President and General Manager of Clinical, Regulatory and Strategic Intelligence at Norstella, speaks with host Bruno Quinney about where AI is having the most material impact today.
Three areas stand out. Patient identification and matching, where AI is replacing passive recruitment with proactive targeting based on real-world data and protocol criteria. Study startup, where AI is compressing timelines that have historically stretched to six, nine, or twelve months. And synthetic control arms, where AI-matched real-world cohorts can replace placebo populations, potentially halving enrolment timelines and cutting the cost of large phase three studies.
Suzanne is direct about the limits too. Study startup remains far from the one-month ideal. Trust in AI outputs requires sourcing, oversight, and time. The human in the loop has not gone away.
The takeaway is practical: start using it, identify where it fits your workflows, and build from there.